Genetic and Clinical Characteristics of Patients With Tumor Mutation Burden‐High Unresectable Pancreatic Cancer and the Efficacy of Pembrolizumab Treatment
The frequency of TMB-high was 4.4%, which is slightly higher than that previously reported. Pembrolizumab demonstrated greater efficacy in patients with MSI-H plus TMB-high while also exhibiting some efficacy in patients with MSS plus TMB-high.
Authors
- Takumi Kinomoto
- Kana Hosokawa
- Yuko Yamaguchi
- Hiroki Kishimoto
- Naotoshi Sugimoto (ORCID: https://orcid.org/0000-0001-9579-690X)
- Kazuhiro Kozumi
- K. Ohkawa
- Takanori Masumoto
- Kaori Mukai
- Tasuku Nakabori
- Yugo Kai
- Makiko Urabe
- Ryoji Takada
- Kenji Ikezawa
- Masaki Kawabata
Institutions
- Kansai Rosai Hospital (JP)
- Osaka International Cancer Institute (JP)
Publication Details
- Journal
- Cancer Reports
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1002/cnr2.70492
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00